Nicholas Brownstone, MD

Precision measurements are necessary to improve the current therapeutic armamentarium in pigmentary disorders.

Clinicians, especially those who see patients with inflammatory and pigmentary disorders, should incorporate alcohol use disorder screening measures into all patient visits.

This article will highlight recently approved psoriasis therapies that will shape the 2024 treatment landscape and provide some exciting updates in the psoriasis management market this coming year and beyond.

Experts discuss enhancing patient outcomes, comparing clobetasol cream concentrations, and more.

Because of the chronic inflammatory state of psoriasis and the immunosuppression produced by some systemic medications, patients with psoriasis may have an increased risk of lymphoma and nonmelanoma skin cancer.

Experts discuss enhancing patient outcomes, topical formulations and epidermal barrier dysfunction, and more.

Experts discuss enhancing patient outcomes, the "mounting mutiny" against topicals, and more.

Cannabis-based personal care products suddenly seem ubiquitous all over the market, where CBD is a featured ingredient in everything from moisturizers and lotions to makeup.

Experts in dermatology share final thoughts on the treatment of plaque psoriasis and the ever-changing treatment landscape.

Benjamin Lockshin, MD, FAAD, highlights diversity in clinical trials as an unmet need in approaching the treatment of plaque psoriasis.

Expert dermatologists discuss the treatment guidelines for plaque psoriasis, and how the decision about treatment is ultimately in the hands of the clinician.

Nicholas Brownstone, MD, and James Q. Del Rosso, DO, comment on the psychological impact of plaque psoriasis on a patient’s quality of life.

Experts in dermatology review a patient case of a 48-year-old man with plaque psoriasis who is having trouble with topical therapy.

Dermatology experts discuss a patient case concerning a 60-year-old woman with chronic intertriginous psoriasis who is taking a biologic drug for inflammatory bowel disease.

Dawn L. Sammons, DO, FAOCD, FAAD, and Benjamin Lockshin, MD, FAAD, review a case of a female patient with a family history of plaque psoriasis.

Experts discuss the unique mechanism of action of tapinarof and its use in the treatment of plaque psoriasis.

James Q. Del Rosso, DO, and Dawn L. Sammons, DO, FAOCD, FAAD, review the efficacy of a new topical agent in the treatment of plaque psoriasis, tapinarof, highlighting the remittive data.

Experts in dermatology discuss newer topical treatments, such as tapinarof, in the management of plaque psoriasis.

Nicholas Brownstone, MD, comments on how newer treatments in plaque psoriasis can impact residency training.

Dawn L. Sammons, DO, FAOCD, FAAD, shares her approach to using topical vs systemic therapy in plaque psoriasis, focusing on patient preference as the driving factor for treatment selection.

Brad Glick, DO, FAOCD, highlights topical therapy as a targeted treatment of plaque psoriasis.

Benjamin Lockshin, MD, FAAD, comments on how the evolution of the pathophysiology of plaque psoriasis has led to more targeted therapies to treat the disease.

Patients with chronic conditions like alopecia areata may experience a reciprocal relationship between their condition and mental health.

Breakthroughs and approvals we can expect in the coming year.

Phototherapy can serve an important role in the therapeutic armamentarium of vitiligo as it is safe, cost-effective, and can treat patients with large areas of disease.

Vitiligo can have a profound effect on mental health and quality of life.

Newly approved laser treatments can be an effective option for the treatment of this common skin disorder.

A recent systematic review on surgical therapies for vitiligo examined surgical therapies such as punch grafting, suction blister epidermal grafting, and cellular grafting techniques

Vitiligo, an autoimmune skin condition that causes depigmentation, can have a large effect on a patient’s quality of life and psychosocial well-being.

Eric Simpson, MD, MCR, and professor of dermatology at Oregon Health & Science University presents exciting new systemic therapy treatment options for atopic dermatitis.